Vaccino pro/contro
Coronavirus: un approccio biochimico alla prevenzione e cura

CI non vaccinati diffondono l'epidemia?

COVID-19: stigmatising the unvaccinated is not justified, 2021

https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02243-1/fulltext#back-bib1

In Germany, 55·4% of symptomatic COVID-19 cases in patients aged 60 years or older were in fully vaccinated individuals,

Italia

Termometro COVID by Stefano Terna

la versione ufficiale del Governo

The effect of COVID-19 vaccination in Italy and perspectives for “living with the virus”, 11 11 2021

d-dimer+clearance

Covid-19: The Rollercoaster of Fibrin(Ogen), D-Dimer, Von Willebrand Factor, P-Selectin and Their Interactions with Endothelial Cells, Platelets and Erythrocytes. 2020

Risposta al vaccino: intensità e durata

Heterogeneous Longitudinal Antibody Responses to Covid-19 mRNA Vaccination
Show all authors
Suzanne M de la Monte, Christine Long, Nicole Szczepanski, ...
First Published October 7, 2021 Research Article
https://doi.org/10.1177/2632010X211049255
Article information
Open AccessCreative Commons Attribution, Non Commercial 4.0 License
Abstract
Background:
Public health measures to stem the coronavirus disease 2019 (COVID-19) pandemic are challenged by social, economic, health status, and cultural disparities that facilitate disease transmission and amplify its severity. Prior pre-clinical biomedical technologic advances in nucleic acid-based vaccination enabled unprecedented speed of conceptualization, development, production, and widespread distribution of mRNA vaccines that target SARS-CoV-2’s Spike (S) protein.

Design:
Twenty-five female and male volunteer fulltime employees at the Providence VA Medical Center participated in this study to examine longitudinal antibody responses to the Moderna mRNA-1273 vaccine. IgM-S and IgG-S were measured in serum using the Abbott IgM-S-Qualitative and IgG2-S-Quantitative chemiluminescent assays.

Results:
Peak IgM responses after Vaccine Dose #1 were delayed in 6 (24%) and absent in 7 (28%) participants. IgG2-S peak responses primarily occurred 40 to 44 days after Vaccine Dose #1, which was also 11 to 14 days after Vaccine Dose #2. However, subgroups exhibited Strong (n = 6; 24%), Normal (n = 13; 52%), or Weak (n = 6; 24%) peak level responses that differed significantly from each other (P < .005 or better). The post-peak IgG2-S levels declined progressively, and within 6 months reached the mean level measured 1 month after Vaccine Dose #1. Weak responders exhibited persistently low levels of IgG2-S. Variability in vaccine responsiveness was unrelated to age or gender.

Conclusion:
Host responses to SARS-CoV-2-Spike mRNA vaccines vary in magnitude, duration and occurrence. This study raises concern about the lack of vaccine protection in as many as 8% of otherwise normal people, and the need for open dialog about future re-boosting requirements to ensure long-lasting immunity via mRNA vaccination versus natural infection.

Vaccinazioni Normativa Ministeriale